Macrophage inhibitory cytokine-1: a novel biomarker for p53 pathway activation.

Macrophage inhibitory cytokine-1: a novel biomarker for p53 pathway activation. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Macrophage inhibitory cytokine-1: a novel biomarker for p53 pathway activation. Abstract Text:

Hong Yang,Zoran Filipovic,David Brown,Samuel N Breit,Lyubomir T Vassilev,

The p53 tumor suppressor protein plays a key function in the cellular response to stress by activating a subset of genes responsible for cell cycle arrest and apoptosis. Activation of the p53 pathway in tumor cells has been proposed as a novel approach to cancer therapy and substantial efforts have been dedicated to the discovery of pharmacological p53 activators. Here, we show that the transforming growth factor-beta superfamily cytokine, macrophage inhibitory cytokine-1 (MIC-1), can serve as a secreted biomarker for activation of p53 in both cellular and xenograft models of human cancer. Using doxorubicin treatment in the HCT116 colon cancer cell line, we have shown that MIC-1 secretion into culture media is correlated with p53 pathway activation as measured by the up-regulation of its downstream transcriptional target p21. When transplanted into nude mice, HCT116 cells continued to secret human MIC-1 and mouse plasma levels correlated well with tumor volume. Treatment of these animals with a single dose of doxorubicin led to activation of the p53 pathway and a nearly 4-fold elevation of the plasma MIC-1 level, which was paralleled by p21 induction in the tumor xenografts. Estimation of MIC-1 concentration, both in vivo and in vitro, represents a novel tool for the study of p53 pathway and development of p53-activating therapeutics.

Macrophage inhibitory cytokine-1: a novel biomarker for p53 pathway activation. Publishing Authors By Initials

H Yang,Z Filipovic,D Brown,SN Breit,LT Vassilev,

For similar proteins: dna-binding proteins: tumor suppressor protein p53 research abstracts see: proteins: dna-binding proteins: tumor suppressor protein p53 research

PUBMED ID PMID:

MEDLINE DATE:

Macrophage inhibitory cytokine-1: a novel biomarker for p53 pathway activation. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Molecular cancer therapeutics

VOLUME: 2

Page Numbers: 1023-9

Journal Abbreviation: Mol. Cancer Ther.

ISSN: 1535-7163

DAY: 19

MONTH: Oct

YEAR: 2003

Macrophage inhibitory cytokine-1: a novel biomarker for p53 pathway activation. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 101132535

Macrophage inhibitory cytokine-1: a novel biomarker for p53 pathway activation. Keywords Mesh Terms:

KEYWORDS: Tumor Suppressor Protein p53

MESH TERMS: metabolism

Chemical & Substance for Abstract: Macrophage inhibitory cytokine-1: a novel biomarker for p53 pathway activation. Information

Substance Name: growth differentiation factor 15

Registry Number: 0

Grant and Affiliation Information for Macrophage inhibitory cytokine-1: a novel biomarker for p53 pathway activation.

AFFILIATION: Discovery Oncology, Roche Research Center, Hoffmann-La Roche Inc., Nutley, NJ 07110, USA.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Mol Cancer Ther

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Macrophage inhibitory cytokine-1: a novel biomarker for p53 pathway activation Related Publications

• A new quantitative RT-PCR method for sensitive detection of dengue virus in serum samples.
• An antibody-based construct carrying DNA-mimotope and targeting CR1(CD35) selectively suppresses human autoreactive B-lymphocytes.
• Anti-inflammatory activity profile of JANEX-1 in preclinical animal models.
• Antiviral effect of thiourea and urea derivatives in experimental foot-and-mouth disease.
• Around or across the Carpathians: colonization model of the Danube basin inferred from genetic diversification of stone loach (Barbatula barbatula) populations.
• Bruton's tyrosine kinase as a new therapeutic target.
• Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation.
• Inflammation-induced enhancement of IgG immunoreactivity.
• Insight into the mechanism of the acquired antibody auto-reactivity.
• Lysosomal exocytosis is impaired in mucolipidosis type IV.
• Macrophage inhibitory cytokine-1: a novel biomarker for p53 pathway activation.
• Selective silencing of DNA-specific B lymphocytes delays lupus activity in MRL/lpr mice.
• Selective silencing of disease-associated B-lymphocytes by chimeric molecules targeting their Fc{gamma}IIb receptor.
• Sensitivity to stimulus onset and offset in the S-cone pathway.
• Synthesis of two peptide mimetics as markers for chemical changes of wool's keratin during skin unhairing process.
• The effect of standing contrast and pattern adaptation on the human visually evoked potential.
• [Cases of mycoplasma abortion in swine]
• [Perineal electrical stimulation and rehabilitation in urinary incontinence and other symptoms of non-neurologic origin.]